Get started
Akero Therapeutics, Inc.Akero Therapeutics, Inc.Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

AKRO chart

Key stats

Market capitalization
‪1.53 B‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.85USD
Net income
‪−151.76 M‬USD
Revenue
—
Shares float
‪57.62 M‬
Beta (1Y)
2.42

About Akero Therapeutics, Inc.

Sector
Health Technology
CEO
Andrew Cheng
Headquarters
South San Francisco
Website
akerotx.com
Employees (FY)
56
Founded
2017
ISIN
US00973Y1082
FIGI
BBG00L9211Y8
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of AKRO is 21.78 USD — it has increased by 0.25% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Akero Therapeutics, Inc. stocks are traded under the ticker AKRO.
Akero Therapeutics, Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Akero Therapeutics, Inc. has a max estimate of 60.00 USD and a min estimate of 42.00 USD.
AKRO earnings for the last quarter are −0.71 USD whereas the estimation was −0.70 USD which accounts for −0.89% surprise. Estimated earnings for the next quarter are −0.83 USD. See more details about Akero Therapeutics, Inc. earnings.
Yes, you can track Akero Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, AKRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Akero Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
AKRO reached its all-time high on Jun 13, 2023 with the price of 58.38 USD, and its all-time low was 7.52 USD and was reached on Jun 13, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 56.00 employees. See our rating of the largest employees — is Akero Therapeutics, Inc. on this list?